Zetagen Announces Publication in Pain Management of Early Data Using ZetaMet™ as a Potential Treatment for Bone Metastases
Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced publication of early, human clinical data in the peer-reviewed journal Pain Management on ZetaMet™ for the treatment bone metastases.
- Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced publication of early, human clinical data in the peer-reviewed journal Pain Management on ZetaMet™ for the treatment bone metastases.
- To view the publication via open access, go to: https://www.futuremedicine.com/doi/10.2217/pmt-2023-0069
ZetaMet™ is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone. - The small molecule has been approved by the U.S. Food and Drug Administration (FDA) since 1971.
- Zetagen is focused on the more than 620,000 people in the United States, and more globally, living with metastatic cancers.